Video

Dr. Eads Discusses the Classification of Gastrointestinal NETs

Jennifer Eads, MD, assistant professor, senior clinical instructor, department of medicine, University Hospitals Cleveland Medical Center, discusses the classification of gastrointestinal neuroendocrine tumors.

Jennifer Eads, MD, assistant professor, senior clinical instructor, department of medicine, University Hospitals Cleveland Medical Center, discusses the classification of gastrointestinal (GI) neuroendocrine tumors (NETs).

The current classification scheme for GI NETs involves using the tumor histology, the Ki-67, and the mitotic index, as parameters for placing a tumor and guiding treatment, says Eads.

Pathological and clinical studies have indicated that the most important determinate of aggressiveness is the tumor differentiation status, Eads explains. This will place the patient’s tumor in the less aggressive or more aggressive G3 category. Patients with poorly-differentiated and higher Ki-67 tumors are placed in the higher category and don’t do as well, with a poor median overall survival of under a year. As for the well-differentiated category, these patients usually have a higher median overall survival and response to therapy, says Eads.

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD